Summary Panel Discussion: Debating the Key Biomarker, Dosing & Development Strategies to Set Up Early ADC Clinical Development for Success

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Summary Panel Discussion: Debating the Key Biomarker, Dosing & Development Strategies to Set Up Early ADC Clinical Development for Success

3:00 pm - Wednesday 14th October 2026

Bring your burning questions to this closing panel session with the main day’s Translational Medicine speakers. Hear the presenters debate and discuss themes across clinical pharmacology and ADC dose escalation, biomarker technologies to select the right patients for the right ADC, and strategies to set up your Phase I ADC development for success

Speakers:

Gilles Gallant

Founder & Principal Consultant

GG Biotech Consulting

Summary Panel Discussion: Debating the Key Biomarker, Dosing & Development Strategies to Set Up Early ADC Clinical Development for Success

Summary Panel Discussion: Debating the Key Biomarker, Dosing & Development Strategies to Set Up Early ADC Clinical Development for Success

Speakers:

Venue

Map

Contact

Join Our Team

About Us

Explore Our Conferences

Stay Connected

Search

Organized By